This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

ARQ 501 in Subjects With Cancer

This study has been completed.
Information provided by:
ArQule Identifier:
First received: January 12, 2004
Last updated: April 27, 2009
Last verified: April 2009

ARQ 501, an investigational anticancer drug, is intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints known to be defective in cancer using the Company's unique biology platform, Activated Checkpoint Therapy™ (ACT).

ARQ 501 has the potential for improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy.

Condition Intervention Phase
Cancer Drug: ARQ 501 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Clinical, Pharmacokinetic Study of ARQ 501 in Subjects With Advanced Solid Tumors

Further study details as provided by ArQule:

Estimated Enrollment: 80
Study Start Date: September 2003
Study Completion Date: January 2007
Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Histologically or cytologically confirmed solid tumor that is metastatic, unresectable or recurrent and for which standard curative or palliative measures do not exist or are no longer effective.
  • ECOG performance status greater than or equal to 1
  • Life expectancy greater than three months
  • Acceptable pretreatment clinical laboratory results

Exclusion Criteria

  • Subjects who have had chemotherapy or radiotherapy within 4 weeks
  • Subjects receiving any other investigational agents
  • Subjects with known untreated brain metastases
  • Subjects receiving hepatic enzyme-inducing antiseizure drugs ("EIASD")
  • Subjects with uncontrolled intercurrent illnesses
  • Pregnant women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00075933

United States, Massachusetts
Dana Farber/Partners CancerCare Inc
Boston, Massachusetts, United States, 02115
United States, Texas
Mary Crowley Medical Research Center
Dallas, Texas, United States, 75201
Sponsors and Collaborators
Principal Investigator: Geoffrey I Shapiro, MD Dana-Farber Cancer Institute
Principal Investigator: C. Casey Cunningham, MD Mary Crowley Medical Research Center
  More Information Identifier: NCT00075933     History of Changes
Other Study ID Numbers: ARQ 501-101
Study First Received: January 12, 2004
Last Updated: April 27, 2009

Additional relevant MeSH terms:
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents processed this record on September 21, 2017